Down syndrome occurs when a person has an extra chromosome. Chromosomes are small units of genes in the body. These chromosomes determine how the body of a baby forms and functions as the baby grows during pregnancy and even after birth. Babies born with Down syndrome have an extra copy of chromosome 21. Patients suffering from Down syndrome have a mild to moderately low IQ and are also slower to speak during childhood than other children. Some common features of Down syndrome include a short neck, a flattened face, small ears, almond-shaped eyes, small hands and feet, and poor muscle tone (loose joints).
COVID-19 Impact Analysis
- COVID-19 is an infectious disease that originated in the Hubei province of Wuhan city in China in December 2019. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11th, 2020.
- At the early phase of the COVID-19 pandemic, there was no availability of specific diagnostic tests to detect the disease in patients. Alternative diagnostic tests were used initially but were not much effective. This unavailability of specific COVID-19 diagnostic tests presented lucrative opportunities for diagnostic manufacturers to introduce their COVID-19 diagnostic kits. Many leading players as well as some start-ups from various countries utilized this opportunity and introduced COVID-19 diagnostics kits into local as well as global markets. These players achieved an edge over other diagnostics players capitalizing on the opportunity from demand for COVID-19 diagnostic tests, which, in turn, helped them in maintaining their revenues in such a crisis.
- However, attributed to the pandemic, supply chain of the raw materials required to manufacture diagnostic devices and products for Down syndrome has been disrupted in many countries. In addition, the market growth of diagnostic products is declining as the manufacturers of these drugs have slowed down their production due to the pandemic. This, in turn, is expected to have a significant impact on the Down syndrome market.
Top Impacting Factors
- The increase in prevalence of Down syndrome and rise in awareness about this condition are the major drivers that propel the growth of the Down syndrome market. Increase in awareness about Down syndrome has allowed people to opt for advanced therapies and novel diagnostic approaches.
- In addition, technological advancements and increase of government support for R&D activities focused on treatment therapies for Down syndrome contribute as drivers for the Down syndrome market growth.
- However, the complications associated with treatments of Down syndrome can act as a restraint for the market. Moreover, long time associated with the launch of diagnostic and treatment products for the condition can also act as a challenge for the players in the Down syndrome market.
Key Market Trends
Product launches by the companies present across the globe are accelerating the growth of the Down syndrome market.
For instance, in April 2017, VeriSeq NIPT solution was launched by Illumina, Inc. in Europe. This product is a CE-IVD market sequencing technology-based approach. It is used for screening chromosomal abnormalities and can provide the chromosomal status in just 10 weeks of gestation.
U.S. dominates the Down syndrome market in the North America region due to increased R&D studies focused on finding better diagnostic and treatment solutions for Down syndrome.
In Europe, Germany leads the Down syndrome market due to the presence of properly connected and equipped distribution channels.
China leads the Asia-Pacific Down syndrome market due to rise in awareness of Down syndrome and therapies that can help the patients suffering from it.
The key players in the Down syndrome market adopt different strategies, such as collaborations, joint ventures with other players, and business expansion, in developing countries to improve their offerings in the Down syndrome market.
Key Benefits of the Report
- This study presents the analytical depiction of the Down syndrome market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the Down syndrome market share.
- The current market is quantitatively analyzed to highlight the Down syndrome growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market.
- The report provides a detailed analysis depending on the competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Down Syndrome Report
- Which are the leading players active in the Down syndrome market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the Down syndrome market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 on the industry?
- What is Down syndrome?
- What are the current and predicted trends in the market?
Down Syndrome Market Report Highlights
| Aspects | Details |
 By Disease Type |
|
 By Treatment |
|
 By End User |
|
 By Region |
|
 Key Market Players | GlaxoSmithKline Plc., Kyowa Kirin Co., Ltd., Bluebird Bio, Inc., Octapharma AG, Novartis Pharmaceuticals Corporation, CSL Limited, Bayer AG, Amgen, Inc., Novo Nordisk AS, Pfizer Inc., Shire, Inc., Jiangsu Hengrui Medicine Co., Ltd. |
Loading Table Of Content...
